Equities

Fate Therapeutics Inc

Fate Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.42
  • Today's Change-0.13 / -5.10%
  • Shares traded1.96m
  • 1 Year change+3.86%
  • Beta1.8653
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments315436616
Total Receivables, Net1.83388.68
Total Inventory------
Prepaid expenses15278.83
Other current assets, total------
Total current assets332502633
Property, plant & equipment, net159176162
Goodwill, net------
Intangibles, net------
Long term investments0.984.94101
Note receivable - long term07.209.87
Other long term assets0.010.030.03
Total assets506706921
LIABILITIES
Accounts payable4.728.278.61
Accrued expenses346048
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.694625
Total current liabilities3911481
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total99108161
Total liabilities138222243
SHAREHOLDERS EQUITY
Common stock0.100.100.10
Additional paid-in capital1,5801,5361,449
Retained earnings (accumulated deficit)(1212)(1051)(769)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.02(1.85)(0.76)
Total equity368484679
Total liabilities & shareholders' equity506706921
Total common shares outstanding999796
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.